home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  IBC's The Impact of Post-Translational & Chemical Modifications on Protein Therapeutics  
  January 10, 2002

Others

 
     
  IBC USA Conferences, Inc., Hilton San Diego Resort, San Diego, CA
May 8-10, 2002


Post-translational modifications of recombinant therapeutic proteins present the biotechnology industry with some of its most complex and current challenges in production, manufacture, and analysis of such therapeutics. Recognizing the biological significance of post-translational modifications and its associated economic impact to the industry, IBC has brought together industry and academic leaders to share their experiences at a unique conference. IBC’s The Impact of Post-Translational & Chemical Modifications on Protein Therapeutics is the only conference where you can learn how to exploit post-translational changes for improving your therapeutic protein and understand how to prevent costly delays caused by unwanted modifications.
 
 
Organized by: IBC USA Conferences, Inc.
Invited Speakers: Keynote Address

The CBER Perspective on Post-Translational and Chemical Modification of Protein Biologics
- Keith Webber, Ph.D., Deputy Director, Division of Monoclonal Antibodies, Office of Therapeutics Research and Review, CBER, FDA
 
Deadline for Abstracts: -
 
Registration: Five Easy Ways to Register!
Phone (508) 616-5550
Fax (508) 616-5522
E-mail reg@ibcusa.com
Mail
IBC USA Conferences, Inc.
One Research Drive, Suite 400A
Westborough, MA 01581-5195
E-mail: jprudhomme@ibcusa.com
 
  Posted by:   James G. Prudhomme  
Host: ntserver.ibcusa.com
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2002 HUM-MOLGEN. All rights reserved. Liability and Copyright.